Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of CN-AML.

Joanne Ramsey, Laura Kettyle, Daniel Sharpe, Nuala Mulgrew, Glenda Dickson, Janet Bijl, Pamela Austin, Nadine Mayotte, Sonia Cellot, Terence Lappin, Shu-Dong Zhang, Ken Mills, Jana Krosl, Guy Sauvageau, Alexander Thompson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The incidence of refractory acute myeloid leukemia (AML) is on the increase due in part to an aging population that fails to respond to traditional therapies. High throughput genomic analysis promises better diagnosis, prognosis and therapeutic intervention based on improved patient stratification. Relevant pre-clinical models are urgently required to advance drug development in this area. The collaborating oncogenes, HOXA9 and MEIS1, are frequently co-overexpressed in cytogenetically normal AML (CN-AML) and a conditional transplantation mouse model was developed that demonstrated oncogene-dependency and expression levels comparable to CN-AML patients. Integration of gene signatures obtained from the mouse model and a cohort of CN-AML patients using statistically significant connectivity Map (sscMap) analysis identified Entinostat as a drug with the potential to alter the leukemic condition towards the normal state. Ex vivo treatment of leukemic cells, but not age-matched normal bone marrow controls, with Entinostat validated the gene signature and resulted in reduced viability in liquid culture, impaired colony formation and loss of the leukemia initiating cell. Furthermore, in vivo treatment with Entinostat resulted in prolonged survival of leukemic mice. This study demonstrates that the HDAC inhibitor Entinostat inhibits disease maintenance and prolongs survival in a clinically relevant murine model of cytogenetically normal AML. © 2013 AlphaMed Press
Original languageEnglish
Pages (from-to)1434-1445
Number of pages12
JournalStem Cells
Volume31
Issue number7
DOIs
Publication statusPublished - Jul 2013

Keywords

  • CN-AML Model
  • HDAC inhibitor
  • Connectivity Map
  • HOXA9-MEIS1
  • Entinostat
  • Therapeutic

Fingerprint Dive into the research topics of 'Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of CN-AML.'. Together they form a unique fingerprint.

Cite this